Market Overview

UPDATE: JP Morgan Downgrades Forest Laboratories to Neutral on Elongated Recovery

Related FRX
Activis Shares Languish Post-Forest Deal
Among A Raft Of Index Changes, Affiliated Managers Group To Join S&P 500
Forest Labs to Buy Furiex Pharma in $1.5B Deal (Fox Business)

JP Morgan downgraded Forest Laboratories (NYSE: FRX) from Overweight to Neutral and lowered its price target from $41 to $37.

JP Morgan said, "While Forest's development efforts have been highly successful and we see meaningful long-term term earnings power for the company, new product launches have lagged our expectations despite a significant ramp in SG&A. With a similar trend potentially repeating itself with several of the company's next-generation product opportunities, we believe Forest could see a more elongated recovery in earnings and along these lines, see better opportunities within our Specialty Pharma coverage."

Forest Laboratories closed at $33.40 on Wednesday.

Latest Ratings for FRX

DateFirmActionFromTo
May 2014UBSMaintainsNeutral
Apr 2014Cantor FitzgeraldMaintainsHold
Apr 2014SunTrust Robinson HumphreyDowngradesBuyNeutral

View More Analyst Ratings for FRX
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (FRX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters